Preferred Label : Mosunetuzumab;

NCIt synonyms : CD20/CD3 BiMAb BTCT4465A; Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A; Mosunetuzumab-axgb;

NCIt definition : A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.;

UNII : LDJ89SS0YG;

CAS number : 1905409-39-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1905409-39-3 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Lunsumio;

Molecule name : RG 7828; BTCT-4465A; BTCT 4465A; RG-7828; RO7030816;

NCI Metathesaurus CUI : CL507850;

Codes from synonyms : 111261;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3476377/fr/lunsumio-mosunetuzumab-lymphome-folliculaire-lf
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
bispecific monoclonal antibodies
Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma
infusions, intravenous
adult
Antineoplastic Agents, Immunological
mosunetuzumab
evaluation of the transparency committee
Mosunetuzumab
lymphoma, follicular

---
https://www.ema.europa.eu/en/medicines/human/EPAR/lunsumio
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Mosunetuzumab
Mosunetuzumab
orphan drug production
lymphoma, follicular
adult
antineoplastic agents
antineoplastic agents
infusions, intravenous
drug interactions
pregnancy
breast feeding
drug approval
europe
drug evaluation, preclinical
mosunetuzumab

---
Nous contacter.
16/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.